FDA Tells Celera KIF6 Test Unapprovable Without Changes

In a letter to the company, FDA told Celera that it may have to collect additional data on clinical utility to demonstrate the safety and effectiveness of its KIF6 Genotyping Assay.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.